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The Ebola virus (EBOV) RNA-dependent RNA polymerase (RdRp) complex consists of the catalytic subunit
of the polymerase, L, and its cofactor VP35. Using immunoﬂuorescence analysis and coimmunoprecipita-
tion assays, we mapped the VP35 binding site on L. A core binding domain spanning amino acids 280–
370 of L was sufﬁcient to mediate weak interaction with VP35, while the entire N-terminus up to amino
acid 380 was required for strong VP35–L binding. Interestingly, the VP35 binding site overlaps with an
N-terminal L homo-oligomerization domain in a non-competitive manner. N-terminal L deletion
mutants containing the VP35 binding site were able to efﬁciently block EBOV replication and
transcription in a minigenome system suggesting the VP35 binding site on L as a potential target for
the development of antivirals.
& 2013 Elsevier Inc. All rights reserved.Introduction
Filoviruses cause a severe hemorrhagic fever in humans with
case fatality rates up to 90%. The ﬁlovirus family is divided into
two genera: Ebolavirus with ﬁve distinct species including Zaire
ebolavirus (EBOV) and Marburgvirus (MARV) with a single species,
Marburg marburgvirus. Along with the rhabdoviruses, paramyxo-
viruses, and bornaviruses, the ﬁlovirus family belongs to the
nonsegmented negative-sense (NNS) RNA viruses of the order
Mononegavirales. The RNA genome of EBOV is about 19 kb in
length and encodes seven structural proteins. Replication and
transcription of the viral genome requires formation of a ribonu-
cleoprotein complex, comprising the viral genome encapsidatedll rights reserved.
hool of Medicine, National
ncord Street, Boston, MA
).
ol of Medicine,
eben, Germany.by the nucleoprotein NP in association with the RNA-dependent
RNA polymerase (RdRp) complex and a viral transcription factor,
VP30. The RdRp complex consists of the catalytic subunit of the
polymerase, L, and the polymerase cofactor VP35 (Mühlberger,
2007; Mühlberger et al., 1999). Minigenome assays revealed that
NP, VP35, and L are essential and sufﬁcient to support viral
replication. For efﬁcient transcription, the transcription factor
VP30 is also required (Enterlein et al., 2006; Groseth et al., 2005;
Martinez et al., 2008, 2011; Mühlberger et al., 1999; Watanabe
et al., 2004).
The polymerase cofactor VP35 is the functional equivalent of
the phosphoprotein P of other NNS RNA viruses (Mühlberger et al.,
1999). It interacts with L and NP leading to the formation of
trimeric complexes in which VP35 serves as a bridge between NP
and L (Becker et al., 1998; Boehmann et al., 2005; Groseth et al.,
2009). In addition, VP35 forms homo-oligomers mediated by
an amino-terminally located coiled-coil motif (Reid et al., 2005;
Zinzula et al., 2009). It was shown for the closely related MARV
that homo-oligomerization of VP35 is a prerequisite for interaction
with L, but is not required for NP binding (Möller et al., 2005).
M. Trunschke et al. / Virology 441 (2013) 135–145136In addition to its function as polymerase cofactor, VP35 plays an
important role in antagonizing cellular antiviral responses. It acts
as type I interferon antagonist by interfering with retinoic acid
inducible gene I (RIG-I)-dependent activation of the interferon
regulatory factor 3 (IRF-3) (reviewed in (Ramanan et al., 2011)),
blocks activation of the double-stranded RNA-dependent protein
kinase PKR (Feng et al., 2007; Schümann et al., 2009) and
suppresses RNA silencing (Fabozzi et al., 2011; Haasnoot et al.,
2007; Zhu et al., 2012).
Much less is known about the major component of the polymer-
ase complex, the large protein L. The EBOV L protein is 2212 amino
acids in length with an estimated molecular mass of 253 kDa
(Volchkov et al., 1999). Comparative sequence analysis of the L
proteins of representative members of the Mononegavirales revealed
six conserved regions (Poch et al., 1990), which were also identiﬁed
in EBOV L (Volchkov et al., 1999). The L proteins of NNS RNA viruses
are thought to contain all catalytic functions required for transcrip-
tion and replication, including RNA-dependent RNA polymerization,
capping, and methyltransferase activities (Poch et al., 1990). To form
the functional polymerase complex, the L proteins need to interact
with P/VP35. The interaction domain for VP35 on MARV L resides
within the ﬁrst 530 amino acids (Becker et al., 1998). Similarly,
the ﬁrst 505 amino acids of EBOV L were shown to be sufﬁcient
to mediate binding to VP35 (Prins et al., 2010). However, the exact
binding domain for VP35 on L has not been determined yet.
In this study, we mapped the VP35 binding domain on the
EBOV L protein. We show that an amino-terminal fragment
spanning amino acids 280–370 is sufﬁcient to mediate weak
L–VP35 binding, whereas strong binding activity was observed
with L fragments spanning the ﬁrst 380 amino acids. In addition
to the VP35 binding domain, we identiﬁed an L homo-
oligomerization domain located in the N-terminal 450 aminoFig. 1. Interaction of the polymerase subunit L, its cofactor VP35 and the nucleoprotei
transfected with pTM1/FlagL or pTM1/NPEBO and analyzed 2 days after transfection by IFA
of NP and FlagL in the absence (top panels) or presence (lower panels) of VP35. (C) Coimm
presence of [35S]-Met using the TnT® T7 Coupled Reticulocyte Lysate System and su
visualized on a Bio Imager plate.acids of L, which does not compete with VP35 binding. Finally,
we used L fragments containing the VP35 binding domain to
inhibit minigenome replication, potentially offering a new anti-
viral strategy against ﬁlovirus infection.Results
VP35 interacts with L and mediates its relocation into NP-derived
inclusions
Interaction between L and VP35 was characterized in cell
culture by immunoﬂuorescence analysis (IFA) and in a cell-free
transcription/translation system followed by coimmunoprecipita-
tion (CoIP). Since no efﬁcient VP35- or L-speciﬁc antibodies were
available at the time of the experiments, L was expressed as a FLAG-
tagged protein and VP35 was used with an HA-tag in the CoIP
studies. For IFA, cells were stained with an anti-EBOV antiserum to
detect NP or an anti-FLAG antibody for detection of FlagL proteins. The
used anti-EBOV antibody recognized neither VP35 nor L in IFA (data
not shown). Interaction between L and VP35 in IFA was determined
indirectly by taking advantage of the colocalization of L with NP-
derived inclusions via VP35 (Becker et al., 1998; Boehmann et al.,
2005; Noda et al., 2011; Schmidt et al., 2011).
When expressed in the absence of other viral proteins, NP
forms cytoplasmic inclusions, while L is distributed homogenously
in the cytoplasm (Fig. 1A). As mentioned above, L relocalizes into
NP-derived inclusions when coexpressed with NP and VP35. In the
absence of VP35, however, L does not colocalize with NP, indicat-
ing that VP35 serves as a linker between L and VP35. To show
relocalization of full-length L into NP-derived inclusions mediated
by VP35, a FLAG-tagged version of L (FlagL) was expressed inn NP. (A) IFA of NP and the N-terminally FLAG-tagged L (FlagL). Huh-T7 cells were
using antibodies directed against NP (red) and FlagL (green). (B) Cellular localization
unoprecipitation analysis of VP35 and L. VP35HA and FlagL were coexpressed in the
bjected to CoIP. Radioactively labeled proteins were separated by SDS-PAGE and
M. Trunschke et al. / Virology 441 (2013) 135–145 137BSR-T7/5 or Huh-T7 cells along with NP in the absence or presence
of VP35. NP formed characteristic cytoplasmic inclusions (Fig. 1B,
top panel, red), while FlagL was homogeneously distributed
throughout the cytoplasm (Fig. 1B, top panel, green) in the absence
of VP35, indicating that L does not interact with NP. When NP,
VP35, and FlagL were coexpressed, most of FlagL was recruited into
the NP inclusions (Fig. 1B, bottom panel, white arrows), conﬁrming
that VP35 is required for relocation of L into the viral inclusions.
Based on these data, we used the altered distribution pattern of
L in cells co-expressing L, VP35, and NP as a readout to determine
L–VP35 interaction.
The interaction of L with VP35 was also conﬁrmed by CoIP. We
ﬁrst tried to perform CoIP analyses using lysates of cells transiently
expressing VP35 and L. However, the combination of immunopre-
cipitation of cell lysates followed by Western blotting led to a high
background due to unspeciﬁc precipitation and/or staining of
cellular proteins. To keep the Co-IP assays as clean as possible, we
ﬁnally used in vitro translated radioactively labeled proteins. In vitro
translation followed by Co-IP was also used by Chandrika et al.
(1995) to map the P binding site on Sendai virus L. FlagL and VP35HA
were translated either individually or simultaneously in vitro in the
presence of [35S]-methionine. Expression of both proteins was
conﬁrmed by SDS-PAGE and subsequent autoradiography (Fig. 1C,
lanes 1–3). Strong expression of VP35HA was observed, which was
diminished in the presence of L (Fig. 1C, lanes 1 and 3). Full-length
FlagL was expressed in very low levels with several bands of lower
molecular mass (Fig. 1C, lane 2; arrow head indicates full-length L).
The lower molecular mass bands were also precipitated with the
anti-FLAG antibody, suggesting that they represent N-terminal FlagL
fragments (Fig. 1C, lane 6). Shorter in vitro translation products are
frequently observed with proteins greater than 100 kDa and are
likely due to incomplete translation of transcripts (Djavadi-
Ohaniance and Friguet, 1996). Concurrent expression of VP35 and
L resulted in a stronger band for full-length FlagL (Fig. 1C, lane 3),
suggesting that either L is stabilized by VP35 or incomplete
translation of the L gene occurs less frequently in the presence of
other translation products. The latter hypothesis is supported by
data showing that full-length L was also more abundant when
coexpressed with EBOV NP, EBOV VP30, or EGFP (data not shown).
Coexpression of FlagL and VP35HA followed by immunoprecipitation
with anti-FLAG resulted in the detection of full-length FlagL, the FlagL
fragments, and VP35HA, indicating that L and VP35 interact (Fig. 1C,
lane 8). Precipitation with the anti-HA antibody resulted in a faint
band for VP35HA but no detectable FlagL, likely caused by the low
levels of precipitated VP35HA.Fig. 2. Deletion mutants of N-terminally tagged EBOV L. The EBOV L protein consists of 2
acids (dotted box; Prins et al., 2010). Due to the lack of an L-speciﬁc antibody, a FLAG
designed (gray boxes): Deletion mutants in which only the C-terminus was truncated (A
had additional deletions at the N-terminus (B). For homo-oligomerization studies the F
All constructs were cloned into the pTM1 vector under the control of the T7 RNA polymTaken together, interaction of L and VP35 was shown by IFA via
the relocation of FlagL into NP inclusions only in the presence of
VP35. In CoIP studies, an anti-FLAG antibody was able to pull down
FlagL and VP35HA. These two assays were used to characterize the
binding domain for VP35 on L.The binding domain for VP35 is located within the ﬁrst 370 amino
acids of L
To determine the location of the binding domain for VP35 on L,
we ﬁrst created 11 C-terminal deletion constructs. These deletion
mutants contained the ﬁrst 100–600 amino acids of the N-terminus
(Fig. 2A). A FLAG-epitope was added to the N-terminus of each
construct allowing for speciﬁc detection by IFA or CoIP studies.
For IFA, the FlagL deletion mutants were expressed in BSR-T7/5
or Huh-T7 cells along with NP in the presence or absence of
VP35HA. At 48 h post transfection, the cells were ﬁxed and stained
with an anti-EBOV antiserum to detect NP, or an anti-FLAG anti-
body for detection of FlagL proteins. As mentioned above, the used
anti-EBOV antibody recognized neither VP35 nor L. Colocalization
of NP-derived inclusions and FlagL fragments, indicating an inter-
action of L with VP35, was observed when the ﬁrst 370 amino
acids of L were present (Fig. 3A, panels g–k). L fragments
comprising the N-terminal 360 amino acids or less were distrib-
uted throughout the cytoplasm (Fig. 3A, panels a–f). Some aggre-
gation of fragment FlagL333 was observed but the aggregates did
not colocalize with NP-derived inclusions (Fig. 3A, panel d). None
of the L fragments colocalized with NP when expressed in the
absence of VP35 (Fig. S1), demonstrating that VP35-L interaction is
essential for relocalization of L into NP inclusions.
CoIP studies were performed with select FlagL deletion mutants
(FlagL600, 450, 380, 370, and 360). The mutants were transcribed
and translated in a cell-free system in the presence or absence of
VP35HA. The resulting proteins were precipitated with an anti-HA
or anti-FLAG antibody conjugated to protein-A agarose. VP35HA
was coprecipitated with FlagL600, 450, and 380 (Fig. 3B, lanes 1, 3,
and 6, middle panel) but not with shorter fragments (FlagL370 and
FlagL360; Fig. 3B, lanes 8 and 10, middle panel). In some precipita-
tion reactions, a protein with a size similar to that of VP35HA was
detected (indicated by an asterisk n). Due to the appearance of the
band in the absence of VP35HA, it is assumed to be a FlagL
degradation fragment or a prematurely terminated translation
product (e.g. Fig. 3B, lane 7, middle panel). Precipitation of the
translation products with an anti-HA antibody targeting VP35HA212 amino acids with a putative VP35 binding domain located in the ﬁrst 505 amino
-epitope was added to the N-terminus (octagon). Two classes of constructs were
) and dual deletion mutants that were lacking the C-terminal 1612 amino acids and
LAG-tag of constructs marked with an asterisk (n) was exchanged with an HA-tag.
erase promoter.
Fig. 3. Interaction of C-terminal L deletion mutants with VP35. (A) Interaction of FlagL deletion mutants with VP35 was analyzed by IFA as described in Fig. 1. NP is stained
red, FlagL mutants green. (B) The interaction of VP35HA and FlagL was conﬁrmed by CoIP after in vitro translation of the proteins as described in Fig. 1. The positions of FlagL
fragments 600 and 450 are indicated on the left; smaller FlagL fragments that were very similar in size (380, 370, and 360) are indicated by FlagLΔ. Lane 5 shows expression
and precipitation of VP35HA only. The asterisk (n) in lanes 4, 7 and 11 indicates a FlagL fragment that runs close to the size of VP35HA. TP, in vitro translation products.
Experiments were performed at least three times with similar outcome and representative images are shown.
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VP35HA with FlagL fragments 600, 450, and 380 was conﬁrmed, but
additionally FlagL370 was detectable (Fig. 3B, lane 8, lower panel).
The discrepancy between the HA and FLAG precipitation results is
likely due to only weak binding of the FlagL370 fragment to VP35HA,
resulting in less stable complexes which were not recovered in the
CoIP assay. However, the protein interaction was strong enough to
recruit FlagL370 into NP inclusions (Fig. 3A, panel g).
In summary, IFA and CoIP data indicate strong VP35–L interac-
tion with FlagL fragments containing the N-terminal 380 amino
acids and weak interaction when only 370 amino acids are
present. Binding to VP35 was not observed for FlagL fragments
containing 360 or less N-terminal amino acids.
The N-terminal 280 amino acids of L are not required for VP35 binding
Next we deleted N-terminal amino acids from FlagL constructs
that already had truncations in the C-terminus (dual deletions) to
further narrow down the VP35 binding domain on L. The ﬁrst setof constructs was based on FlagL600 that contained the 600 N-
terminal amino acids (Fig. 2A). The ﬁrst 200–300 amino acids (in
20-aa iterations) were deleted to generate the mutants depicted in
Fig. 2B. To conﬁrm protein expression, the constructs were in vitro
translated using the TnT® translation system and detected by
autoradiography. All constructs except FlagL220–600 were correctly
expressed, leading to protein products of the estimated molecular
mass (data not shown). The constructs were analyzed for interac-
tion with VP35HA in IFA and CoIP studies. In IFA studies, FlagL
constructs FlagL200–600 to FlagL280–600 colocalized with NP
(Fig. 4A, panels a–d). Construct FlagL300–600, comprising amino
acids 300–600, was not relocalized into NP-derived inclusions
(Fig. 4A, panel e). In the CoIP analysis, however, none of the in vitro
translated C- and N-terminally truncated FlagL constructs were able
to precipitate VP35HA (Fig. 4B, middle panel, lanes 3, 5, and 7),
while the FlagL600 control interacted strongly with VP35HA (Fig. 4B,
middle panel, lane 9). Vice versa, after precipitation of VP35HA
none of the C- and N-terminal FlagL deletion constructs were
detected (Fig. 4B, bottom panel, lanes 3, 5, and 7). Again, the
Fig. 4. Interaction of N- and C-terminally truncated FlagL mutants with VP35. (A) Interactions of FLAG-tagged L mutants containing deletions at the C- and N-terminus with
VP35 were analyzed by IFA. Red: NP; green: FlagL. (B) CoIP analysis of radioactively labeled FlagL fragments and VP35HA. Proteins were expressed using the TnT® T7 system,
precipitated with either an anti-HA or anti-FLAG antibody and resolved on an SDS-polyacrylamide gel. The resulting autoradiograph is shown. TP, in vitro translation
products. Experiments were performed at least three times with similar outcome and representative images are shown.
M. Trunschke et al. / Virology 441 (2013) 135–145 139control construct FlagL600 coprecipitated with VP35HA (Fig. 4B,
lower panel, lane 9). This indicated only weak interactions of the
dual deletion mutants with VP35HA that were disrupted during the
CoIP procedures.
The combined results from N-terminal and dual, i.e. C- and
N-terminal, deletion mutants of FlagL suggested that the core
binding domain of L with VP35 resides within aa 280 and 370.
However, for strong binding of VP35 to L amino acids 1–380 were
required.
An L homo-oligomerization domain located in the N-terminus does
not compete with VP35 binding
To our knowledge homo-oligomerization of ﬁlovirus L proteins
has not been described yet. It has been shown for Sendai virus
(SeV), also a member of the order Mononegavirales, that the large
polymerase subunit possesses a homo-oligomerization domain
in the N-terminus (Smallwood et al., 2002). The formation of
L homo-oligomers was essential for proper polymerase function
(Cevik et al., 2003). Based on our data, the interaction domain of
L with VP35 is located within the N-terminus between aa 280 and
370. We therefore analyzed the N-terminus for the presence of an
L homo-oligomerization domain and potential competition
between L–L and L–VP35 complex formation by CoIP studies.
To analyze the formation of L homo-oligomers, two L proteins
based on FLAG-tagged constructs were generated, in which the
FLAG-tag was replaced by an HA-tag: HAL (full length) and HAL600
(Fig. 2A, marked with asterisk). All proteins were detected after
expression in the TnT® T7 system and in Western blot analysis oftransfected cells. L homo-oligomerization is examined by CoIP of
HA- and FLAG-tagged proteins. Despite many attempts, the pre-
cipitation of full-length HAL was unsuccessful. Since it is known for
the L proteins of various paramyxoviruses that the L–L oligomer-
ization domain resides in the N-terminus (see discussion), further
studies were performed using HAL600. Construct HAL600 was
coexpressed in the TnT® T7 system with FLAG-tagged L deletion
mutants described earlier (FlagL450, FlagL380, FlagL370, and FlagL340)
(Fig. 5A, top panel). Precipitation of the reaction products with an
anti-FLAG antibody revealed that only the longest construct,
FlagL450, was able to efﬁciently precipitate HAL600 (Fig. 5A, bottom
panel, lane 3). A faint protein band migrating at the size of HAL600
was consistently observed with FlagL380 (Fig. 5A, bottom panel,
lane 5). However, since there was a background band at approxi-
mately the same size in the sample without HAL600 (Fig. 5A, bottom
panel, lane 4), it remained elusive whether or not fragment
FlagL380 weakly interacted with HAL600. Shorter deletion mutants
containing the N-terminal 370 or 340 amino acids failed to
precipitate HAL600. These results indicate that EBOV L harbors
an L homo-oligomerization domain in the N-terminal 450
amino acids.
It was now of interest to investigate whether the L homo-
oligomerization and the VP35 binding domains in the N-terminus
overlap in a way that L and VP35 binding is competitive. To
address the question of competition for L binding, HAL600 and
FlagL450 were coexpressed in the TnT® T7 system with increasing
amounts of VP35HA. Translation products were precipitated with
an anti-FLAG antibody. The intensities of the protein bands after
SDS-PAGE were determined in TINA 2.09 to calculate the ratio of
Fig. 5. The homo-oligomerization domain in the N-terminus of EBOV L does not compete with VP35 binding. (A) In vitro translation products (TP) and CoIP analysis of
HAL600 with various FLAG-tagged L fragments using an anti-FLAG antibody. (B) Impact of VP35HA on L homo-oligomerization. HAL600 and FlagL450 were in vitro translated in
the presence of increasing amounts of VP35HA. The ratio of HAL600 and VP35HA relative to FlagL450 was determined before (gray bars) and after (black bars) CoIP with an anti-
FLAG antibody. The average of three experiments is shownwith standard deviations. (C) Representative gels used for the quantiﬁcation shown in Fig. 5B. Upper panel, in vitro
translation products (TP); bottom panel, CoIP using an anti-FLAG antibody. (D) Comparison of expression and coprecipitation levels of FlagL600 and VP35HA when expressed
separately (lane 1) or concurrently (lane 2). Single expression is shown in lanes 3 and 4. The experiment was performed three times and a representative gel is shown.
M. Trunschke et al. / Virology 441 (2013) 135–145140HAL600 to FlagL450 and VP35HA to FlagL450 before and after
precipitation. Competition for the binding site in the N-terminus
of L would result in less coprecipitation of HAL600 in the presence
of increasing amounts of VP35HA (or an increase of the VP35HA to
FlagL450 ratio). As shown in Fig. 5B and C no difference in the ratios
of precipitated HAL600 and VP35HA relative to FlagL450 was
observed. These data indicate that binding domains for VP35 and
L, although located in overlapping regions in the N-terminus of L,
do not compete.
Formation of the functional polymerase complex could occur
either by binding of VP35 to preformed L oligomers or by
cotranslational L–VP35 interaction. To distinguish these possibili-
ties, VP35 and L were either expressed separately and mixed prior
to CoIP or concomitantly synthesized in the in vitro translation
system before they were subjected to CoIP. Although VP35 still
bound to L when the proteins were mixed after synthesis, bindingwas strongly reduced, indicating that cotranslation of the two
proteins is required for efﬁcient binding (Fig. 5D, lanes 1 and 2).
In summary, EBOV L forms homo-oligomers where the inter-
action site resides within the N-terminal 450 amino acids. CoIP
studies showed no competition between L and VP35 binding to L.
Additionally, VP35–L binding is enhanced when the two proteins
are concurrently expressed.
EBOV transcription and replication can be inhibited by L peptides
Since our results revealed that the N-terminal domain of EBOV
L plays a crucial role in both L–L oligomerization and L–VP35
interaction, the question arose of whether it would be possible to
inhibit EBOV transcription and replication by disrupting the
polymerase complex using N-terminal L peptides. First, we tested
the tagged L proteins for their ability to mediate transcription and
M. Trunschke et al. / Virology 441 (2013) 135–145 141replication in a modiﬁed minigenome assay (Mühlberger et al.,
1999). Constructs HAL, FlagL and FlagL600, respectively, were trans-
fected into BSR-T7/5 cells along with the CAT-expressing mini-
genome 3E–5E and supporter plasmids for expression of VP35,
VP30, and NP. Untagged full-length L was transfected as positive
control. The HA-tag did not negatively impact polymerase activity
whereas the FLAG-tag reduced transcription and replication to 16%
(data not shown). FlagL600 was not able to support transcription
and replication, conﬁrming the importance of the C-terminus for
polymerase function (data not shown).
For inhibition studies, we tested most of the previously
described C-terminal L deletion mutants and the dual deletion
mutants (Fig. 2A and B). Additionally, we designed L peptides
which were 130 amino acids in length from various positionsFig. 6. Inhibition of polymerase activity by expression of L fragments. (A) Schematic of
described in Fig. 2. (B) Dual luciferase assay results. BSR-T7/5 cells were transfected with
the ﬁreﬂy luciferase-expressing minigenome 3E–5E_F-luc. Additionally, 0.5 mg of the L d
indicated by ﬁreﬂy luciferase activity. As transfection efﬁciency control 0.3 mg of a renill
renilla and ﬁreﬂy luciferase activity were measured. Results were normalized to the level
additional L fragment as 100%. The average values of 3 independent experiments are sh
expressing minigenome (3E–5E) instead of 3E–5E_F-luc to evaluate inhibition of replicat
were subjected to Western blot analysis using an anti-Flag antibody.inside the L protein; a 130 amino acid long peptide based on the
cat gene was designed as negative control (Fig. 6A). Inhibition
analysis of L fragments was performed in a quantitative dual
luciferase minigenome assay. BSR-T7/5 cells were transfected with
one of the L peptide plasmids or the CAT peptide plasmid along
with plasmids encoding EBOV NP, VP35, VP30, L, and the mini-
genome. Inhibition was calculated relative to samples without
additional peptides. L fragments containing at least the N-terminal
380 amino acids were able to suppress transcription and replica-
tion to less than 15% (Fig. 6B). These fragments were also able to
interact with VP35 as shown in IFA (Fig. 3A) and CoIP (Fig. 3B).
Interestingly, peptides that interacted with VP35 in IFA but not
CoIP (e.g. FlagL370 or FlagL200–600) did not impair polymerase
function. This strongly supports the notion that the interactionspeptides used for polymerase inhibition studies in addition to L deletion mutants
plasmids encoding L, NP, VP35, and VP30 to enable transcription and replication of
eletion mutant was transfected to evaluate the impact on polymerase function as
a luciferase-expressing plasmid was co-transfected. Cells were lysed after 24 h and
s of renilla luciferase and graphed as relative expression setting the sample without
own with standard deviation as error bars. (C) Representative result using a CAT-
ion (top). Expression control of L fragments (bottom). Cell lysates used for CAT assay
M. Trunschke et al. / Virology 441 (2013) 135–145142of these fragments with VP35 are weaker than interactions
between full-length L and VP35, resulting in displacement of the
peptides with higher-afﬁnity full-length L. The results shown in
Fig. 6B were conﬁrmed by cat gene-based minigenome assays
using a selection of L fragments. Only fragments spanning at least
the ﬁrst 380 aa of L were able to block replication and transcrip-
tion of the minigenome, while shorter fragments were not
(Fig. 6C).
In conclusion, we show that the EBOV L protein harbors both
the VP35 binding and L homo-oligomerization domain in the N-
terminal 450 amino acids. More speciﬁcally, weak VP35 binding
was observed with fragments spanning amino acids 280–370.
However, only larger fragments containing at least the ﬁrst 380
amino acids were able to coprecipitate VP35HA indicating stronger
interactions. Finally we were able to demonstrate that polymerase
function could be inhibited by these L peptides. This ﬁnding might
be helpful to design speciﬁc inhibitors of the EBOV polymerase for
use as a therapeutic.Discussion
Replication and transcription of NNS RNA viruses are complex
events that require several viral (and presumably host) proteins.
The L protein of all NNS RNA viruses studied so far must interact
with the phosphoprotein (P/VP35) to form a functional replicase
and transcriptase complex. Despite this general requirement, there
are virus-speciﬁc differences regarding the mechanisms of L–P
interaction and the location of the binding sites on both proteins.
The VP35 binding domain on L of both MARV and EBOV is located
in the N-terminal part of the protein. In our study, the VP35
binding domain on EBOV L was mapped to the ﬁrst 380 N-terminal
amino acids. Since VP35–L interaction was observed with a MARV
L deletion mutant spanning the ﬁrst 530 amino acids, but not with
a mutant comprising the ﬁrst 309 amino acids of L (Becker et al.,
1998), it is assumed that the VP35 binding domain on MARV L is
located in the same region as shown for EBOV L. Similar to
ﬁloviruses, the P binding site of several members of the Paramyx-
oviridae family was found to be located in the N-terminal part of
the L proteins, including measles virus (MeV), rinderpest virus
(RPV), SeV, simian virus 5 (SV5), and human parainﬂuenza viruses
(hPIV) 2 and 3 (Cevik et al., 2003, 2004; Chandrika et al., 1995;
Chattopadhyay and Shaila, 2004; Holmes and Moyer, 2002;
Horikami et al., 1994; Nishio et al., 2011; Parks, 1994; Smallwood
and Moyer, 2004). The identiﬁed binding regions ranged from
1305 amino acids in the case of hPIV3 to 380 amino acids for RPV,
which is exactly the size of the VP35 binding region on EBOV L
(Chattopadhyay and Shaila, 2004; Smallwood and Moyer, 2004).
Sequence comparison analysis of multiple NNS RNA L proteins
revealed four highly conserved aa stretches in the N-terminal part
of the proteins (Poch et al., 1990). Mutations in any of these
regions abrogated P binding of SeV L (Holmes and Moyer, 2002).Fig. 7. Proposed binding model of L and VP35. (A) Linear representation of the L prote
diagonal stripes and dots, respectively. The homo-oligomerization domain is represente
Mononegavirales are indicated by I–VI (Poch et al., 1990).The identiﬁed aa stretches are also conserved in EBOV L. Notably,
region 4 spans amino acids 368–383 in EBOV L which have been
shown to be crucial to stabilize VP35–L binding. Three of the four
highly conserved aa stretches are located in domain I, a conserved
region present in the L proteins of NNS RNA viruses (Poch et al.,
1990). Domain I spans aa 226–426 of EBOV L and overlaps with the
VP35 and L interaction domains ((Volchkov et al., 1999), Fig. 7).
Mutational analysis of SeV L domain I resulted in a spectrum of
diverse phenotypes, including deﬁciency in P binding and uncou-
pling of transcription and replication, indicating that domain I is
involved in multiple functions of the L protein (Chandrika et al.,
1995).
In contrast to ﬁlo- and paramyxoviruses, amino acids important
for P binding of rhabdoviral L proteins were mapped within the C-
terminal part (Canter and Perrault, 1996; Chenik et al., 1998). CoIP
analysis of vesicular stomatitis virus (VSV) L and P showed that
both an N-terminal L fragment comprising the ﬁrst 1593 amino
acids of L and a C-terminal fragment spanning amino acids 1594–
2109 bound P, although less efﬁciently than full-length L, suggest-
ing that an intact L tertiary structure is a prerequisite for P binding
(Rahmeh et al., 2010). This is clearly different to EBOV, corroborat-
ing L gene-based phylogenetic analyses showing that ﬁloviruses
are more closely related to paramyxoviruses than to rhabdoviruses
(Mühlberger et al., 1992; Volchkov et al., 1999).
While P–L interactions were examined extensively, few para-
myxoviral L proteins have been analyzed for L–L interaction. Of the
ones analyzed, the identiﬁed L–L interaction domains are located
in the N-terminal part of L, overlapping with the P binding
domains similar to EBOV L (Cevik et al., 2004; Nishio et al., 2011;
Smallwood et al., 2002; Smallwood and Moyer, 2004). Despite the
overlap of the EBOV L homo-oligomerization domain with the
VP35 binding site, no competition between L–L and L–VP35
binding was observed (Fig. 5). Similarly, non-competing over-
lapping L–L and L–P interaction domains were mapped on MeV
and SeV L proteins. L homo-oligomerization and binding to P are
mediated by different amino acids located in the N-terminus of L
(Cevik et al., 2003, 2004). Also, oligomerization of MeV and SeV L
proteins does not require P, which has also been observed for
EBOV L.
To date, the order of L–L, L–P, and P–P binding events for most
viruses is not completely understood. Coexpression studies
revealed that SV5 L and P did not coimmunoprecipitate when
expressed separately and mixed prior to CoIP, indicating that
simultaneous expression of the two proteins in the same cell is
required for L–P complex formation (Parks, 1994). This is different
for rabies virus L and P which are able to interact when combined
after separate expression (Chenik et al., 1998). Similarly, recombi-
nant puriﬁed VSV or SeV L and P proteins formed transcriptionally
functional complexes when mixed after puriﬁcation (Ogino et al.,
2005; Rahmeh et al., 2010). Our data indicate that FlagL600–VP35
interaction is strongly enhanced upon coexpression, although
weak co-precipitation was still observed when the two proteins
were expressed separately and mixed prior to CoIP (Fig. 5D).in. The core and complete binding domain for VP35 on L are shown as boxes with
d by a box with horizontal stripes. Six regions that are conserved within the order
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homo-oligomerization has been proposed for hPIV3 (Chattopadhyay
and Banerjee, 2009). Although oligomerization of SeV and MeV L
proteins takes place in the absence of P, P has been implicated in the
stabilization of L for SeV, SV5, MeV, and VSV when coexpressed in
cells, most likely by preventing misfolding and degradation (Canter
and Perrault, 1996; Horikami et al., 1992, 1994; Smallwood et al.,
1994). Recombinant puriﬁed VSV, SeV, and Chandipura virus L
proteins are stable in the absence of P, whereas puriﬁed respiratory
syncytial virus L seems to require P for stabilization (Morin et al.,
2012; Noton et al., 2012; Ogino and Banerjee, 2010; Ogino et al.,
2005; Rahmeh et al., 2009). In our hands in vitro transcribed full-
length EBOV FlagL was more abundant in the presence of VP35
(Fig. 1C, lanes 2 and 3). However, the same effect was observed
when L was co-expressed with EBOV NP, EBOV VP30, or EGFP (data
not shown), suggesting that co-translational activity leads to
enhanced synthesis or stabilization of full-length L in an in vitro
translation system.
A common feature of NNS RNA virus P proteins is that they
form homo-oligomers, typically tetramers. Oligomerization of
ﬁloviral VP35 proteins and the P proteins of many members of
the order Mononegavirales is mediated by coiled-coil motifs
(Bousse et al., 2001; Curran et al., 1995; Möller et al., 2005; Reid
et al., 2005). For MARV it was shown that an intact coiled-coil
motif on VP35 is a prerequisite for VP35–L interaction (Möller
et al., 2005). A possible interpretation of these data is that L binds
to preformed VP35 oligomers. It is also conceivable that the coiled-
coil domain is not only involved in VP35 oligomerization but also
in L binding.
The requirement of EBOV L to oligomerize and interact with
VP35 in order to form functional polymerase complexes could be
exploited to develop antiviral drugs. L fragments binding to VP35
and/or L inhibited replication in an EBOV minigenome system
(Fig. 6). A similar observation was reported for SeV. An L fragment
comprising the ﬁrst 895 amino acids of SeV L blocked viral
transcription (Cevik et al., 2003). In conclusion, our data show
that blocking the formation of the EBOV replication complex is a
promising approach for antiviral interventions.Materials and methods
Cells
The baby hamster kidney cell line BSR-T7/5 constitutively expres-
sing the T7 RNA polymerase (kindly provided by K. K. Conzelmann,
Max von Pettenkofer Institute and Gene Center, Munich, Germany)
was cultured as described in Buchholz et al. (1999). The human
hepatoma cell line Huh-T7 constitutively expressing the T7 RNA
polymerase (kindly provided by V. Gaussmüller, Department of
Medical Molecular Biology, University of Lübeck, Germany) was
grown in DMEM supplemented with 10% FCS and 1 mg/ml geneticin
(Schultz et al. 1996).
Construction of L mutants
Generation of plasmids containing nucleocapsid genes of Zaire
ebolavirus, Mayinga isolate, has been described elsewhere
(Mühlberger et al., 1999). Plasmid pTM1/LEBO (Mühlberger et al.,
1999) was used as template for the L mutants. All L fragments used
for immunoﬂuorescence and immunoprecipitation studies con-
tained either an N-terminal FLAG- or HA- epitope. We chose to
N-terminally tag the proteins because this is a well established and
widely used approach in the ﬁeld. Full-length pTM1/FlagL was
obtained by ligation of an annealed oligonucleotide pair coding for
the FLAG-epitope into the NotI restriction site of pTM1/LEBO.Mutants lacking the C-terminus were obtained by PCR ampliﬁca-
tion using pTM1/FlagL as template. The forward primer contained
an NcoI restriction site and the start codon of the FLAG-epitope
while the reverse primers were complementary to the last 24
nucleotides of the L-coding sequence followed by a stop codon and
a SacI restriction site. The PCR fragments were cloned into the
pTM1 plasmid using the NcoI and SacI restriction sites. For homo-
oligomerization studies, the FLAG-tag of constructs marked with
an asterisk (n) was exchanged with an HA-tag (Fig. 2A). The FLAG-
tag was excised with NotI and an annealed oligonucleotide
encoding the HA-tag was ligated into the vector. Mutants with
deletions in both the N- and C-terminus were obtained by PCR
ampliﬁcation of the respective L fragment ﬂanked by the coding
sequence of the FLAG-epitope and a stop codon and cloned into
pTM1. All positive clones were veriﬁed by DNA sequencing.
In vitro translation
Proteins were translated in a cell-free system (TnT® T7 Coupled
Reticulocyte Lysate System, Promega) in the presence of L-[35S]-
methionine (Readyvue™ Pro-mix; GE Healthcare Europe or Easy
Tag 35S-Methionine; Perkin Elmer) as described by the manufac-
turer. Brieﬂy, 0.1–1.5 μg of each expression plasmid and 1.0 μL of
L-[35S]-met were added to 20–40 μL of TnT® T7 Quick Master Mix
on ice. The volume was adjusted to 25–50 μL with nuclease-free
H2O. The transcription/translation reaction was performed at 30 1C
for 90 min.
Coimmunoprecipitation
Protein-A sepharose (Sigma-Aldrich) was equilibrated and
washed three times with Tris/KCl wash buffer (10 mM Tris,
150 mM KCl, 0.5% NP-40). Five mL of the in vitro translation products
were diluted with Tris/KCl buffer (wash buffer with 3% BSA) and
centrifuged at 13,000 rpm for 20 min at 4 1C. The clariﬁed super-
natant was pre-adsorbed to 20 μL of protein-A sepharose for 1 h.
After brief centrifugation the supernatants were incubated with the
speciﬁc antibody for 1 h at 4 1C. FLAG-tagged proteins were incu-
bated with a mouse monoclonal anti-FLAG M2 antibody (1:500;
Sigma-Aldrich) and HA-tagged proteins with a mouse monoclonal
anti-HA-7 antibody (1:5000; Sigma-Aldrich). Protein–antibody com-
plexes were incubated overnight with 20 μL of protein-A sepharose
and precipitated by low-speed centrifugation. Alternatively, cell
lysates were incubated directly with anti-FLAGM2 or anti-HA clone7
agarose without pre-adsorption. Proteins were precipitated by
incubation with the agarose for 2 h at 4 1C followed by low-speed
centrifugation. The pellets were washed three times with Tris/KCl
buffer and once with Tris/KCl wash buffer. Bound proteins were
eluted with 4x Laemmli buffer at 95 1C for 5 min and separated
using SDS-PAGE. Radioactively labeled proteins were detected using
a BioImager Analyzer (Fuji BAS-1000) and the Raytest TINA software.
Transfection of cells
BSR-T7/5 or Huh-T7 cells were grown in 6-well plates to 60–70%
conﬂuence and transfected using FUGENE 6 (Roche Molecular
Applied Science). Transfection was carried out as previously
described (Modrof et al., 2002). For minigenome assays, 1.0 μg
pTM1/LEBO, 0.5 μg pTM1/NPEBO, 0.5 μg pTM1/VP35EBO, 0.1 μg pTM1/
VP30EBO, and 0.5 μg of pC-T7/Pol expressing the T7 RNA polymerase
(kindly provided by T. Takimoto, St. Jude Children's Research
Hospital, Memphis, TN and Y. Kawaoka, University of Wisconsin,
Madison, WI) were transfected (Mühlberger et al., 1998; Neumann
et al., 2002). To analyze minigenome activity based on the chlor-
amphenicol acetyltransferase (CAT) reporter gene, 1.0 μg minige-
nome DNA (3E–5E) was co-transfected. For analysis of minigenome
M. Trunschke et al. / Virology 441 (2013) 135–145144activity based on ﬁreﬂy luciferase expression, 1.0 μg of 3E–5E_F-luc
was transfected with 0.3 μg of pRL-SV40 (expressing Renilla lucifer-
ase as transfection control; Promega). For inhibition assays, 0.5 μg of
L peptide plasmid DNA or CAT peptide plasmid DNAwas transfected
along with the EBOV minigenome plasmids. For immunoﬂuores-
cence analysis, BSR-T7/5 or Huh-T7 cells were seeded on glass
coverslips in 6-well plates, allowed to grow to 60–70% conﬂuence
overnight, and transfected the next day with the plasmids of interest
(0.25 μg pTM1/NPEBO, pTM1/VP35EBO, and 1.0 μg for L-expressing
plasmids), either individually or in combination. All transfections
were adjusted to the same total amount of DNA using empty pTM1
plasmid.Enzymatic CAT assay
BSR-T7/5 cells were transfected as described above. At 2 days
post transfection, cell pellets were washed twice with PBS and
lysed in 150 μl of reporter lysis buffer (Promega). CAT assays were
performed using either a standard protocol (Modrof et al., 2002) or
using a ﬂuorescent substrate (FAST CAT) following the manufac-
turer's protocol (Molecular Probes). Quantiﬁcation of radioactive
chloramphenicol was done with a BioImager Analyzer (Fuji BAS-
1000) and the Raytest TINA software. Fluorescent samples were
detected in the GelDoc system using QuantityOne-4.0.0 software
(Bio-Rad).Dual luciferase assay
Dual luciferase activity of cell lysates was determined using the
Dual-Luciferase reporter assay system (Promega) according to
the manufacturer's protocol. Luminescence was measured using
the LUMIstar luminometer (BMG).Western blot analysis
Cell lysates in reporter lysis buffer (Promega) obtained for dual
luciferase or CAT reporter assay were mixed with SDS loading
buffer and separated by SDS PAGE. Proteins were then transferred
to a PVDF membrane via semi-dry blotting. FlagL fragments were
detected using anti-Flag M2 antibody (Sigma-Aldrich) followed by
staining with an Alexa Fluor 680-conjugated secondary antibody
(Molecular Probes).Immunoﬂuorescence analysis
BSR-T7/5 or Huh-T7 cells seeded on glass coverslips were
transfected with plasmids as described previously. At 48 h post
transfection, cells were ﬁxed and permeabilized with a 1:1
mixture of acetone:methanol for 5 min at −20 1C. After washing
three times with PBS the coverslips were ﬁrst blocked with 0.1 M
glycine for 10 min then with IFA blocking solution (PBS with 2%
BSA, 0.2% Tween-20, 3% glycerol, 0.05% NaN3) for another 10 min.
A goat anti-EBOV antiserum (1:00; kindly provided by S. Becker,
University of Marburg, Marburg, Germany) was used to detect NP.
This antiserum recognized neither VP35 nor L in IFA. A monoclonal
mouse anti-FLAG M2 antibody (Sigma-Aldrich; 1:200) was used to
detect FLAG-tagged proteins. A donkey anti-goat antibody coupled
with Alexa Fluor® 594 (Invitrogen, 1:500) and a FITC-conjugated
donkey anti-mouse antibody (Dianova; 1:100) were used as
secondary antibodies. Antibodies were diluted in IFA blocking
solution as indicated.Acknowledgments
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